shire plc (SHPGF) Key Developments
Shire plc Announces Availability of New Titration Strength of ADHD Drug
Mar 25 15
Shire plc has announced the availability of Vyvanse 10mg capsules indicated for the treatment of attention-deficit/hyperactivity disorder, or ADHD. This new titration dose, which was approved by the FDA on October 30, 2014, is the seventh Vyvanse dosage strength available in addition to the 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsule strengths. In July 2014, Shire received approval for two additional administration options for Vyvanse capsules. In addition to swallowing whole or mixing the capsule contents with water, the contents can be mixed with yogurt or orange juice for patients who have trouble swallowing capsules.
Shire Reportedly Mulls Acquisition Of Ironwood Pharmaceuticals
Mar 19 15
Shire plc (LSE:SHP) is reportedly seeking acquisition of Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD). Market sources reported that Ironwood Pharmaceuticals has been approached by European suitors, including Shire, 35p better at 5635p, and rejected cash offers in the region of $30 a share. Ironwood Pharma jumped 5% to $16.47.
Genfit Reportedly Mulls Sale
Mar 4 15
Genfit SA (ENXTPA:GNFT) is reportedly exploring the option of selling itself. According to people familiar with the matter, Genfit SA has also held preliminary discussions with potential strategic buyers. According to the sources, Genfit has yet not made a any decision and there is a possibility that it may not sell at all. The potential buyers include Sanofi (ENXTPA:SAN), Shire plc (LSE:SHP) and Novartis AG (SWX:NOVN).
Shire plc Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults
Mar 2 15
Shire plc announced that the company has submitted a New Drug Application (NDA) with the U. S. Food and Drug Administration for its investigational compound lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. The NDA submission is supported by the totality of evidence from four clinical trials with more than 1,800 patients. These included one Phase 2 study, two Phase 3 efficacy and safety studies, and one long-term Phase 3 safety study.
Investors Reportedly Eyes Stake In PTCT
Feb 23 15
PTC Therapeutics, Inc. (NasdaqGS:PTCT) is exploring a potential sale amid takeover interest from Shire plc (LSE:SHP) and BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), according to people familiar with the matter. PTCT is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Representatives for could not be reached for comment. Representatives for Shire and BioMarin declined to comment. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.